We can’t show the full text here under this license.
Using once-weekly injectable GLP-1 therapy to manage multiple aspects of type 2 diabetes
Updated
Abstract
Once-weekly glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may provide benefits in managing complications of type 2 diabetes (T2D).
- Recent findings indicate GLP-1 RAs can help manage complications such as cardiovascular disease, retinopathy, neuropathy, and nephropathy in T2D.
- Dulaglutide and semaglutide may offer cardiovascular benefits for patients at high risk of cardiovascular events compared to standard treatments.
- These medications may provide renal protection for patients with chronic kidney disease.
- Cost-effectiveness studies suggest that once-weekly GLP-1 RAs are more cost-effective compared to alternative therapies.
- GLP-1 RAs may improve overall health-related quality of life by reducing the risk of depression and diabetes-related distress, while also limiting hypoglycaemia.
Simplified
Key numbers
463 million
Global Diabetes Prevalence
Adults living with diabetes as of 2019
USD 16,750
Cost of Diabetes Care
Estimated annual healthcare costs per person with diabetes in 2017
112%
Increased Treatment Costs with CVD
Annual treatment costs for patients with diabetes and cardiovascular disease vs. those without